Tag: Bayer

Xarelto

Xarelto (rivaroxaban) reduces risk of major amputation by 70% in peripheral...

Bayer and its cooperation partner Janssen Research & Development have announced two publications of further data from the Phase III COMPASS study in The...
Xarelto

ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and...

The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...